Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Condition(s) studied
Investigational drug(s) / intervention(s)
GLP-1 receptor agonist: Semaglutide: weekly subcutaneous administration, starting dose 0.25mg, maintenance dose 1mg
SGLT2 inhibitor: dapagliflozin: oral administration from 5 to 10mg/day
Tirzepatide: subcutaneous injection: starting dose 2.5 mg, maintenance 5mg (weekly administration)
Other drugs: Patients not under SGLT2i or GLP-1RA influence, but receiving other treatments which are part of CKD standard care: mineralocorticoid receptor agonists, metformin, ACE inhibitors, ARBs...
Study summary
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The accumulation of fat tissue around the organs in conditions of obesity or diabetes accelerates the production of pro-inflammatory factors that may worsen the kidney and heart damage. New antidiabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA), have proven beneficial effects on the kidney and heart due to several mechanisms, including anti-inflammatory actions and a potential action on the fat tissue.
The aim of this study is to assess the link between adiposopathy and CKD, by investigating the changes in adiposopathy measures throughout treatment with GLP-1RA to a sample of patients with CKD.
Eligibility
Primary outcome measure(s)
- Ultrasonography change in perirenal adipose tissue thickness — 16 months
Change in perirenal adipose tissue thickness as measured with ultrasonography - Change in estimated glomerular filtration rate — 16 months
Change in eGFR as per the CKD-EPI formula
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Vithas Valencia Consuelo | Valencia | Valencia | Recruiting |
On this site
📄 Mounjaro (tirzepatide) drug profile →More Cardenal Herrera University trials in Spain
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07309094 on ClinicalTrials.gov ↗ ← All trials in Spain